The oral formulation would be huge, if it's possible. K clearly needs more than weekly dosing, and oral also allows for fewer clinical visits and vastly cheaper administration. They must try for a pill or subcutaneous implant. Also, the really short (2 hour) half life could be a huge impediment to therapeutic dosing, making a better delivery an imperative. Hopefully it is the sole reason we didn't see more consistent therapeutic response in the Phase 1.
Very pleased to see K moving, and in a clear direction!